Adaptive Biotechnologies Launches $250M Convertible Senior Notes Offering Due 2031 To Repay OrbiMed Debt, Fund Share Repurchases, And Support Growth Initiatives

Loading news article.

Adaptive Biotechnologies Launches $250M Convertible Senior Notes Offering Due 2031 To Repay OrbiMed Debt, Fund Share Repurchases, And Support Growth Initiatives | WAPE

Adaptive Biotechnologies Launches $250M Convertible Senior Notes Offering Due 2031 To Repay OrbiMed Debt, Fund Share Repurchases, And Support Growth Initiatives

Article summary

Related companies

Comments —